We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AFYA Welcomes 300 Operational Medical School Seats in Salvador
Read MoreHide Full Article
Afya Limited (AFYA - Free Report) completed the acquisition of the total share capital of Unidom Participacoes S.A. (Unidompedro and Faculdade Dom Luiz) through its wholly-owned subsidiary Afya Participacoes S.A.
This strategic buyout will provide Afya with 300 operational medical school seats in Brazil’s Salvador city. The average purchase price of this strategic transaction was R$ 660.0 million, of which R$ 347.8 million is already paid (net debt deduction) and the remaining R$ 312.2 million will be paid in about 10 annual installments of R$31.2 million each.
The authorization request for the 300 seats was made to the Ministry of Education ("MEC") before the Mais Medicos Law was enacted and MEC concluded its analysis and issued Ordinance 630/2020. Currently, among the 300 authorized seats of Unidompedro, 125 seats are final and the remaining 175 seats are subject to a conclusion of the Ordinance 630/2020 review by the MEC upon judicial order in 2021.
If Unidompedro wins the bid processes in the Mais Medicos 3 Program, an additional payment of R$250 thousand per granted seat will be made.
Afya expects an EV/EBITDA of 4.2x upon the maturity of this transaction and beyond. In 2027, at the medical school's full maturity, expected net revenues will be R$ 267 million, of which more than 95% will be contributed by Medicine.
Price Performance
Shares of this medical education group and medical practice solutions provider in Brazil gained 21.4% in the past year compared with the Zacks Schools industry’s 46.4% growth. Although the company underperformed the industry, its focus on accretive buyouts, operational restructuring efforts and other initiatives offering top-tier medical education services will likely boost its growth in the upcoming period.
Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 and second-quarter earnings per share of AFYA have, respectively, been revised upward to $1.63 from $1.56, and to 37 cents from 35 cents, in the past 30 days. The estimated figures indicate 27.3% and 27.6% year-over-year growth, respectively.
The growth trend is solidified by a VGM Score of A, backed by a Value Score and a Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential.
AGS has a trailing four-quarter earnings surprise of 40%, on average. The Zacks Consensus Estimate for AGS’ 2024 sales and earnings per share (EPS) implies growth of 7.7% and 5,166.7%, respectively, from the year-ago levels.
Adtalem Global Education Inc. (ATGE - Free Report) currently sports a Zacks Rank of 1. ATGE has a trailing four-quarter earnings surprise of 18.8%, on average.
The consensus estimate for ATGE’s fiscal 2025 sales and EPS indicates an increase of 5.3% and 16.6%, respectively, from the year-ago levels.
La-Z-Boy Incorporated (LZB - Free Report) currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average.
The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AFYA Welcomes 300 Operational Medical School Seats in Salvador
Afya Limited (AFYA - Free Report) completed the acquisition of the total share capital of Unidom Participacoes S.A. (Unidompedro and Faculdade Dom Luiz) through its wholly-owned subsidiary Afya Participacoes S.A.
This strategic buyout will provide Afya with 300 operational medical school seats in Brazil’s Salvador city. The average purchase price of this strategic transaction was R$ 660.0 million, of which R$ 347.8 million is already paid (net debt deduction) and the remaining R$ 312.2 million will be paid in about 10 annual installments of R$31.2 million each.
The authorization request for the 300 seats was made to the Ministry of Education ("MEC") before the Mais Medicos Law was enacted and MEC concluded its analysis and issued Ordinance 630/2020. Currently, among the 300 authorized seats of Unidompedro, 125 seats are final and the remaining 175 seats are subject to a conclusion of the Ordinance 630/2020 review by the MEC upon judicial order in 2021.
If Unidompedro wins the bid processes in the Mais Medicos 3 Program, an additional payment of R$250 thousand per granted seat will be made.
Afya expects an EV/EBITDA of 4.2x upon the maturity of this transaction and beyond. In 2027, at the medical school's full maturity, expected net revenues will be R$ 267 million, of which more than 95% will be contributed by Medicine.
Price Performance
Shares of this medical education group and medical practice solutions provider in Brazil gained 21.4% in the past year compared with the Zacks Schools industry’s 46.4% growth. Although the company underperformed the industry, its focus on accretive buyouts, operational restructuring efforts and other initiatives offering top-tier medical education services will likely boost its growth in the upcoming period.
Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 and second-quarter earnings per share of AFYA have, respectively, been revised upward to $1.63 from $1.56, and to 37 cents from 35 cents, in the past 30 days. The estimated figures indicate 27.3% and 27.6% year-over-year growth, respectively.
The growth trend is solidified by a VGM Score of A, backed by a Value Score and a Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential.
Zacks Rank & Other Key Picks
Afya currently carries a Zacks Rank #2 (Buy).
Here are other top-ranked stocks from the Consumer Discretionary sector.
PlayAGS, Inc. (AGS - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
AGS has a trailing four-quarter earnings surprise of 40%, on average. The Zacks Consensus Estimate for AGS’ 2024 sales and earnings per share (EPS) implies growth of 7.7% and 5,166.7%, respectively, from the year-ago levels.
Adtalem Global Education Inc. (ATGE - Free Report) currently sports a Zacks Rank of 1. ATGE has a trailing four-quarter earnings surprise of 18.8%, on average.
The consensus estimate for ATGE’s fiscal 2025 sales and EPS indicates an increase of 5.3% and 16.6%, respectively, from the year-ago levels.
La-Z-Boy Incorporated (LZB - Free Report) currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average.
The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels.